Resolian at EBF 2026

Nov 17–19, 2026 Barcelona, Spain ~800 attendees Website

Resolian brings 3 presentations to EBF 2026 in Barcelona. Its program spans ADA and neutralizing antibody validation for biosimilars, PK in nasal mucosal lining fluid and a hybrid LC–MS/MS assay made more sensitive with microflow chromatography.

Organization	EBF 2026 Attendance
Resolian Malvern, Pennsylvania	◇Sponsor
resolian.com Bioanalytical CROsSponsor Bioanalytical and CMC analytical CRO formed from LGC's drug development business and Alliance Pharma, with labs in the US, UK, China and Australia.	Talk Tue Nov 17 2:40–3pm Part of Session 6: Biosimilars Demonstrating Antigenic Equivalence Across Biosimilars and Reference Products: ADA and NAb Assay Validation Strategies Through Real-World Case Studies Immunogenicity Talk Wed Nov 18 9:20–9:40am Part of Session 10: Bioanalysis Beyond Conventional Matrices Bioanalytical Challenges of PK Assessment in Nasal Mucosal Lining Fluid for a Novel Antiviral Therapeutic Sampling Talk Thu Nov 19 9–9:20am Part of Session 16: Protein MS tech 1 Extending the Sensitivity of a Hybrid LC-MS/MS Assay for PAD2 and PAD4 Through Microflow Chromatography LC–MS

Organization

EBF 2026 Attendance

Resolian

Malvern, Pennsylvania

resolian.com

Bioanalytical CROsSponsor

Bioanalytical and CMC analytical CRO formed from LGC's drug development business and Alliance Pharma, with labs in the US, UK, China and Australia.

Talk

Tue Nov 17
2:40–3pm

Part of Session 6: Biosimilars

Demonstrating Antigenic Equivalence Across Biosimilars and Reference Products: ADA and NAb Assay Validation Strategies Through Real-World Case Studies

Immunogenicity